Back to Sites

Bronx-Lebanon Hospital IMPAACT

Site Number

5114

Address

Bronx-Lebanon Hosp. IMPAACT CRS
1685 Morris Ave
Suite 1 G
Bronx, NY 10457
United States of America

IMPAACT Members at this Site

Martha Cavallo CRS Coordinator

Mahboobullah Mirza-Baig Investigator

Caroline Nubel Investigator

Studies at this Site

P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir

DAIDS Number

11773

Research Area

Therapeutics

P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure and Immunotherapy

Study Status

Enrolling

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

38609

Research Area

Therapeutics

Study Status

Closed to Accrual

IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

DAIDS Number

38637

Research Area

Therapeutics

Study Status

Closed to Accrual

IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV

DAIDS Number

38693

Research Area

Cure and Immunotherapy

Study Status

Enrolling

IMPAACT 2029: Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV

DAIDS Number

38717

Research Area

Treatment

Study Status

Withdrawn

IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States

DAIDS Number

38746

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2017: MOCHA

DAIDS Number

30070

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1

DAIDS Number

38962

Research Area

Therapeutics

Study Status

Pending

IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV

DAIDS Number

39052

Research Area

Therapeutics

Study Status

Pending